Skip to main content
. 2018 Jan 26;97(4):e9757. doi: 10.1097/MD.0000000000009757

Figure 2.

Figure 2

Kaplan–Meier survival curves for patients receiving sorafenib prescribed by oncologists or GI/Hep. No significant differences were identified by Kaplan–Meier or Cox proportional hazard methodologies. GI/Hep = gastroenterology/hepatologists.